TAS-103

• CAT Number: I002277
• CAS Number: 174634-08-3
• Molecular Formula: C₂₀H₁₉N₃O₂
• Molecular Weight: 333.38
• Purity: ≥95%
• Target: Topoisomerase
• Solubility: 10 mM in DMSO
• Storage: Store at -20°C
• IUPAC Name: 6-[2-(dimethylamino)ethylamino]-3-hydroxyindeno[2,1-c]quinolin-7-one
• InChI: InChI=1S/C20H19N3O2/c1-23(2)10-9-21-20-18-17(13-5-3-4-6-14(13)19(18)25)15-8-7-12(24)11-16(15)22-20/h3-8,11,24H,9-10H2,1-2H3,(H,21,22)
• InChIKey: ROWSTIYZUWEOMM-UHFFFAOYSA-N
• SMILES: CN(C)CCNC1=NC2=C(C=CC(=C2)O)C3=C1C(=O)C4=CC=CC=C43

TAS-103（Cat No.:I002277）, also known as tasisulam, is an experimental chemotherapy drug being investigated for its potential in treating various cancers, including solid tumors. It is a novel sulfonamide compound that exerts its effects by interfering with DNA replication and inhibiting cancer cell division. TAS-103 has shown promise in preclinical and early clinical trials for its ability to target tumor cells while potentially minimizing damage to healthy tissues. Currently, it is undergoing further clinical evaluation to determine its safety, efficacy, and optimal use in cancer treatment. Side effects and long-term outcomes are still being assessed.